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INTRODUCTION
This chapter addresses the management of BP in adult CKD
patients (specifically non-dialysis-dependent CKD [CKD
ND]) without diabetes mellitus. There is overlap with BP
management in the elderly (defined as persons 465 years of
age or as persons with CKD and aging-related co-morbid
conditions). In the elderly in particular and to a lesser extent
in younger CKD patients, these co-morbid conditions may
require modifications in the approach to BP management.
In this chapter we consider two primary adverse outcomes
related to high BP: progression of kidney disease and
development of CVD.137,138 The data are sufficient to provide
recommendations on BP targets139 and the use of ACE-Is or
ARBs, although there is evidence of heterogeneity in both
areas according to the urine albumin level.96,140–142 We
therefore divided the target populations on the basis of urine
albumin level.
We did not find sufficient data to suggest any differences
according to CKD stage, so our recommendations are not
stage-specific. It is not possible to recommend specific
regimens or BP targets for all the various causes of CKD.
Although there are strong observational data, there is no
evidence from RCTs to indicate that the treatment approach
should differ substantially for the patient with glomerular
disease and high urine albumin levels compared to the
patient with severe renovascular disease. Although we would
have preferred to give a target range (lowest to highest) for
BP rather than a single target for highest acceptable BP, there
are insufficient data based on RCTs to recommend a target
for lowest BP level. The recommendations and suggestions in
this chapter therefore emphasize an approach based on
highest acceptable BP and severity of albuminuria, but the
interventions should be implemented cautiously and with
subsequent surveillance for adverse effects.
We also recognize that BP agents other than those
recommended or suggested below, such as diuretics, may
be necessary for BP control, especially as CKD progresses and
volume retention becomes more of an issue. However, few
RCTs addressing hard cardiovascular or kidney outcomes
have randomized patients to a diuretic versus another agent
on top of an ACE-I or ARB. Therefore, in contrast to the
2004 KDOQI guideline,1 we do not provide a guideline
statement regarding diuretic use as a preferred second-line
agent. The use of diuretics and other BP agents are discussed
in more detail below and in Chapter 2.
3.1: We recommend that non-diabetic adults with CKD
ND and urine albumin excretiono30mg per 24 hours
(or equivalent*) whose office BP is consistently
4140mmHg systolic or 490mmHg diastolic be
treated with BP-lowering drugs to maintain a BP that
is consistently r140mmHg systolic and r90mmHg
diastolic. (1B)
*Approximate equivalents for albumin excretion rate per 24 hours—
expressed as protein excretion rate per 24 hours, albumin/creatinine ratio,
protein/creatinine ratio, and protein reagent strip results—are given in
Table 1, Chapter 1.
RATIONALE
K High BP is a risk factor for CVD and development and
progression of CKD.
K Lowering BP in the general population reduces cardio-
vascular risk.
K Lowering BP in CKD patients reduces the rate of CKD
progression.
K CKD is a major risk factor for CVD.
Most recent BP guidelines have suggested a target BP of
o140/90mmHg for all individuals who are not at high risk
for CVD.1,143 This is based on several lines of evidence,
including observational data suggesting that high BP is a risk
factor for CVD,144 observational data suggesting that high BP
is a risk factor for development and progression of
CKD,145–148 RCTs of BP agents in the general population
showing a benefit of a lower target BP,149,150 and RCTs in the
general population demonstrating that the treatment of BP
reduces CVD outcomes.151
Several previous guidelines for kidney disease have
recommended a BP target ofo130/80mmHg for all patients
with CKD, irrespective of the level of urine protein.1,143 These
recommendations are primarily based on observational data
in the general population showing that the presence of CKD,
irrespective of the level of urine protein, is associated with
high risk of CVD.152,153 In addition, data from the MDRD
study, which randomized patients to a mean arterial pressure
(MAP) ofo92mmHg (equivalent to 125/75mmHg) versus
107mmHg (equivalent to 140/90mmHg) showed that tight
BP control reduced progression of kidney disease in patients
with41 g of urine protein per 24 hours.142
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Since the publication of previous guidelines, several events
have resulted in more caution about advocating a BP target
of r130/80mmHg in CKD patients without albuminuria.
RCTs in CKD populations have shown that data from the
general population cannot necessarily be extrapolated to the
CKD population.26,27 Moreover, particularly in RCTs related
to anemia, the RCT findings may be inconsistent with
observational data.154,155 Guideline agencies156,157 are now
requiring more rigorous data, in particular from RCTs, as a
basis for recommendations. Several manuscripts have re-
cently emphasized that tight BP control may have adverse
effects,22,158 particularly in the elderly and those with CAD
and low diastolic BP.40 Furthermore, less tight control (i.e.,
control involving the use of fewer drugs) may improve
adherence and reduce costs of treatment, a benefit particu-
larly relevant in resource-poor environments.
Finally, several recent RCTs have not shown a benefit of
lower BP targets in patients without proteinuria. For
instance, the African American Study of Kidney Disease
and Hypertension (AASK) randomized participants to treat-
ment to a MAP of eitherr92mmHg or 102 to 107mmHg.140
During the long-term follow-up of participants, there was a
benefit associated with the lower BP target among patients
with a urine protein/creatinine ratio (PCR) of 4220mg/g
(422mg/mmol), but not among those with a PCRr220mg/
g (r22mg/mmol). In fact, in some analyses, there was a trend
toward worse outcomes in those targeted to low BP when the
urine PCR was r220mg/g (r22mg/mmol). Similarly, in the
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
trial,159 no benefit was found with regard to the primary
composite outcome with a systolic BP target o120mmHg
versus a target of o140mmHg.
We therefore propose that targets currently recom-
mended in the general population be extrapolated to those
with CKD who do not have elevated urinary albumin or
protein levels. Results of subgroup analyses of CKD patients
included in RCTs assessing target BPs are consistent
with the primary results of these trials160 (Supplementary
Table 1 online). This move towards a more conservative
target is consistent with other guidelines.161 We have graded
this recommendation as 1B, given that this BP target is
currently considered the standard of care for the general
population.
3.2: We suggest that non-diabetic adults with CKD ND
and urine albumin excretion of 30 to 300mg per 24
hours (or equivalent*) whose office BP is con-
sistently 4130mmHg systolic or 480mmHg dia-
stolic be treated with BP-lowering drugs to maintain
a BP that is consistently r130mmHg systolic and
r80mmHg diastolic. (2D)
*Approximate equivalents for albumin excretion rate per 24 hours—
expressed as protein excretion rate per 24 hours, albumin/creatinine ratio,
protein/creatinine ratio, and protein reagent strip results—are given in
Table 1, Chapter 1.
RATIONALE
K Urine albumin level of 30 to 300mg per 24 hours
(microalbuminuria) is a risk factor for CVD and CKD
progression.
K RCTs suggest that a BP r130/80mmHg may reduce
progression of CKD.
Patients with microalbuminuria are at high risk for progres-
sion of CKD as well as development of CVD.18,153,162165
RCT data suggest that BP control is particularly important in
CKD patients with high urine albumin levels.
Short-term follow-up data from the MDRD study142
showed an interaction of BP target with level of urine
protein, with a definitive benefit for kidney outcomes in
patients with 41 g of urine protein per 24 hours and GFR
of 25–55m/min per 1.73m2 (in MDRD Study A), with a
trend toward a benefit with lower protein levels. Long-term
follow-up showed a benefit of a low target BP and no
interaction with the urine protein level, suggesting that the
benefit may extend to all protein levels. In subgroup
analyses, the benefit was statistically significant in those
with urine protein excretion of 40.3 g per 24 hours166
(H Tighiouart, personal communication). However, there
may have been insufficient statistical power to detect the
interaction; hence, the risk reduction may have been greater
in those with higher urine protein levels. Long-term follow-
up data from the MDRD study also showed a benefit with
regard to kidney outcomes with a lower target BP in specific
groups, such as patients with polycystic kidney disease and
non-glomerular diseases, that frequently have low urine
albumin levels. Long-term follow-up in the AASK study
demonstrated a benefit of lower target BPs in patients with
a PCR 4220mg/g (422mg/mmol).140 It is unclear
whether this PCR cutoff can be translated into an
albumin-level cutoff, as this conversion is likely to be
dependent on the type of kidney disease, and the ratio of
glomerular albuminuria to tubular proteinuria. In the
Effect of Strict Blood Pressure Control and ACE-Inhibition
on Progression of Chronic Renal Failure in Pediatric
Patients (ESCAPE) study,14 a lower BP target was of benefit
in reducing the risk of kidney outcomes, particularly in
children with higher urine protein levels (P¼ 0.06 for
interaction of treatment target with urine protein level).
There have been no BP target trials involving CKD
patients focused on hard CVD outcomes. Subgroup
analyses from the Hypertension Optimal Treatment (HOT)
trial167 did not show a benefit for CVD outcomes in
association with a lower diastolic BP target in CKD patients,
although the statistical power to detect a difference was
limited (n¼ 470 for those with a creatinine level41.5mg/dl
[133 mmol/l]). Furthermore, albuminuria data were not
available.
Because patients with CKD and microalbuminuria
are at high risk, and given that the evidence does
not support using different BP targets in non-diabetics
and diabetics (see Chapter 4), the Work Group suggests
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a BP target of r130/80mmHg. This ensures consistency
among recommendations between persons with diabetes and
those without diabetes and facilitates implementation into
clinical practice.
3.3: We suggest that non-diabetic adults with CKD ND
and urine albumin excretion 4300mg per 24 hours
(or equivalent*) whose office BP is consistently
4130mmHg systolic or 480mmHg diastolic be
treated with BP-lowering drugs to maintain a BP
that is consistently r130mmHg systolic and
r80mmHg diastolic. (2C)
*Approximate equivalents for albumin excretion rate per 24 hours—
expressed as protein excretion rate per 24 hours, albumin/creatinine ratio,
protein/creatinine ratio, and protein reagent strip results—are given in
Table 1, Chapter 1.
RATIONALE
K Albuminuria is a major risk factor for CVD and CKD
progression.
K RCTs show that BP r130/80mmHg may reduce
progression of CKD in patients with urine albumin
excretion 4300mg per 24 hours (‘macroalbuminuria’).
Patients with macroalbuminuria are at very high risk for both
progression of CKD and development of CVD.18,162,163
Observational data suggest that hypertension is a risk factor
for CVD and progression of CKD in patients with macro-
albuminuria.168 As noted above, short-term follow-up data
from the MDRD study142 showed an interaction of BP target
with the level of urine protein, with a definitive benefit in
patients with a urine protein level 41 g per 24 hours (in
Study A) and a trend toward a benefit with lower protein
levels; long-term follow-up data showed a benefit of a lower
target BP. In subgroup analyses, a benefit was noted in
patients with urine protein excretion 40.3 g per 24 hours166
(H. Tighiouart, personal communication). Long-term fol-
low-up data from AASK also showed a benefit of a lower
target BP in patients with PCR 4220mg/g (422mg/
mmol),140 and the ESCAPE trial14 showed a benefit in the
entire population with a borderline interaction of treatment
target and urine protein level.
In summary, we believe there is sufficient evidence to
suggest a BP target ofr130/80mmHg for kidney protection
in those with macroalbuminuria. We have graded this
suggestion 2C, for the following reasons. The reported
benefits in the AASK and the MDRD study are based on post
hoc and subgroup analyses. Furthermore, in both the MDRD
study and AASK, MAP was targeted rather than systolic and
diastolic BP, and a specific MAP may translate into different
systolic and diastolic BP, depending on the individual patient.
Additionally, in the MDRD study, a higher MAP was targeted
in patients over the age of 60 years.169 The Ramipril Efficacy
in Nephropathy 2 (REIN-2) study did not show a benefit of
tight BP control, although admittedly this was a short-term
study with relatively few outcomes and it is unclear whether
the use of a dihydropyridine calcium-channel blocker
(felodipine) in the low-target arm may have confounded
the results170 (See Supplementary Tables 2–4 online). We also
do not believe that this recommendation should in any way
hinder trials from randomizing patients with CKD and urine
protein excretiono1 g per 24 hours to various BP targets, as
there is sufficient equipoise and uncertainty to endorse these
trials. One such trial that will evaluate this question is Systolic
Blood Pressure Intervention Trial (SPRINT) which is funded
by National Institutes of Health (NIH).171,172 It will evaluate
cardiovascular and kidney outcomes in patients randomized
to a systolic BP ofo140mmHg versuso120mmHg. There
is a CKD component for patients with GFR 20–60ml/min/
1.73 m2. Patients with diabetes and those with 24-hour urine
protein excretion of 41 g per 24 hours are excluded from
this study.
3.4: We suggest that an ARB or ACE-I be used in non-
diabetic adults with CKD ND and urine albumin
excretion of 30 to 300mg per 24 hours (or
equivalent*) in whom treatment with BP-lowering
drugs is indicated. (2D)
*Approximate equivalents for albumin excretion rate per 24 hours—
expressed as protein excretion rate per 24 hours, albumin/creatinine ratio,
protein/creatinine ratio, and protein reagent strip results—are given in
Table 1, Chapter 1.
RATIONALE
K Urine albumin excretion of 30 to 300mg per 24 hours
(microalbuminuria) is a risk factor for CVD and CKD
progression.
K ACE-Is and ARBs have been shown to reduce urine
albumin levels.
K RCTs suggest that ACE-Is or ARBs may help reduce
progression of CKD and possibly CVD in patients with
urine albumin excretion of 30 to 300mg per 24 hours.
As mentioned above, patients with microalbuminuria are at
high risk for both progression of CKD and development of
CVD.18,162165 Here, we describe the trial data which either
focused on kidney disease or CVD outcomes. Some trials
focused on both.173176
Kidney disease. In AASK, a study of patients with a PCR
o220mg/g (o22mg/mmol), the ACE-I ramipril decreased
the urine protein level. It remains to be determined whether
this translates into a clinically important benefit.177 In post
hoc analyses of the Heart Outcomes Prevention Evaluation
(HOPE), which was an RCT involving patients with diabetes
or vascular disease and at least one other CVD risk factor,
ramipril prevented progression of proteinuria or develop-
ment of new-onset microalbuminuria, independent of
diabetes status.174 In a post hoc analysis of Candesartan
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Antihypertensive Survival Evaluation in Japan (CASE J),
which was an RCT comparing the ARB candesartan with the
calcium-channel blocker amlodipine,178 candesartan reduced
progression of CKD 4 (see Supplementary Table 5 online). In
subgroup analyses of the Telmisartan Randomized Assess-
ment Study in ACE Intolerant Subjects with Cardiovascular
Disease (TRANSCEND), an RCT that included patients with
vascular disease or diabetes, in patients with microalbumi-
nuria (defined as an ACR 43.4mg/mol [434mg/g]), the
ARB telmisartan decreased the risk of the composite kidney
outcome (doubling of SCr level, dialysis, or death) in
comparison with placebo.179 There was an interaction
whereby telmisartan benefited patients with microalbumi-
nuria but was associated with harm in those without
microalbuminuria (P¼ 0.006 for interaction). Finally, in
patients with diabetes, ACE-Is and ARBs have been shown to
prevent the development of macroalbuminuria in subjects
with microalbuminuria,180,181 and we have not found
evidence of substantive differences between diabetics and
non-diabetics with respect to either BP target or agent.
The Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT) was a large RCT
examining the effects of the ACE-I lisinopril, the thiazide
chlorthalidone, and the dihydropyridine calcium-channel
blocker amlodipine in individuals 455 years of age with
hypertension and at least one other CVD risk factor.
Lisinopril did not show a benefit for doubling of creatinine
or kidney failure when compared with chlorthalidone in the
entire cohort or among patients with CKD at baseline175 (see
Supplementary Table 6 online). ALLHAT, however, did not
permit the use of an ACE-I with a diuretic—a combination
that is frequently required in clinical practice to achieve
adequate BP control.182184 In addition, the diuretic arm in
ALLHAT achieved better BP control making comparison of
agents more difficult to interpret. Unfortunately, albuminuria
or proteinuria status was not measured in the enrolled
subjects, but assuming that ALLHAT was consistent with
other trials of high-risk individuals recruited from the
general population (e.g., HOPE or TRANSCEND), the
median level of proteinuria was most likely below the
microalbuminuria cutoff.
CVD. There have been few RCTs of BP agents that have
focused on CVD outcomes in CKD patients without diabetes
mellitus (Supplementary Tables 7–32 online). Most of the
data are taken from subgroup analyses of patients with CKD
from general population studies (Supplementary Tables 1,
5–6, 33–36 online). HOPE showed a benefit for CVD
outcomes in patients randomized to ramipril.185 This benefit
extended to those with a creatinine level 41.4mg/dl
(124mmol/l) or a creatinine clearance o65ml/min (1.1ml/
sec) in non-diabetic individuals,173 as well as those with
microalbuminuria.185 In the Perindopril Protection Against
Recurrent Stroke Study (PROGRESS), which included
patients with a history of cerebrovascular disease, the ACE-
I perindopril, as compared with placebo, decreased the rate of
recurrent stroke in those with CKD.186 Although the level of
urine albumin was not specified in PROGRESS, it seems
reasonable to assume that CVD protection would extend to
those with microalbuminuria. In patients with stable
coronary disease in the Prevention of Events with Angio-
tensin-Converting Enzyme Inhibitor Therapy (PEACE) trial,
the ACE-I trandolapril, as compared with placebo, reduced
mortality in those with a GFR o60ml/min/1.73m2,
although trandolapril did not have a benefit in those with
a GFR Z60ml/min/1.73m2.187 However, the effect of
trandolapril therapy on outcomes was not significantly
modified by the level of albuminuria.188 In the European
Trial on Reduction of Cardiac Events with Perindopril in
Stable Coronary Artery Disease (EUROPA), there was no
modification of benefit by level of kidney function, and
perindopril (versus placebo) decreased the risk of the
primary composite end point of cardiovascular death, non-
fatal myocardial infarction, or resuscitated cardiac arrest in
patients with a GFR o75ml/min/1.73 m2 as well as those
with a GFR 475ml/min/1.73 m2.189 ALLHAT, however, did
not show a benefit of lisinopril over chlorthalidone with
respect to CVD outcomes in the subgroup of patients with
CKD.176
The Prevention of Renal and Vascular Endstage
Disease Intervention Trial (PREVEND IT) included CKD
patients with urine albumin levels of 15mg to 300mg per
24 hours. Patients were randomized to the ACE-I fosinopril
or placebo. Fosinopril decreased albumin excretion by 26%
and showed a trend toward reducing the risk of CVD
outcomes (hazard ratio [HR] versus placebo 0.60; 95% CI
0.33–1.10).190 Similarly, in the CASE J trial, candesartan
reduced the rate of CVD outcomes, as compared with
amlodipine, in CKD 4 patients178 (Supplementary Table 5
online).
The Work Group suggests ACE-Is or ARBs as the
preferred class of BP-modifying agent in CKD patients with
microalbuminuria. This recommendation is based on
observational data and subgroup and post hoc analyses,
hence the grade of 2D.
3.5: We recommend that an ARB or ACE-I be used in
non-diabetic adults with CKD ND and urine
albumin excretion 4300mg per 24 hours (or
equivalent*) in whom treatment with BP-lowering
drugs is indicated. (1B)
*Approximate equivalents for albumin excretion rate per 24 hours—
expressed as protein excretion rate per 24 hours, albumin/creatinine ratio,
protein/creatinine ratio, and protein reagent strip results—are given in
Table 1, Chapter 1.
RATIONALE
K Urine albumin excretion 4300mg per 24 hours
(‘macroalbuminuria’) is a risk factor for CVD and for
CKD progression.
K In RCTs involving patients with CKD and urine albumin
excretion4300mg per 24 hours, ARBs or ACE-Is reduce
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the risks of ‘hard’ outcomes such as the doubling of SCr
level, kidney failure, or death.
Patients with macroalbuminuria are at very high risk for both
progression of CKD and development of CVD.18,162,163
Kidney disease. Several trials have demonstrated a benefit,
in patients with macroalbuminuria, of ACE-Is or ARBs over
either placebo or other agents, in reducing the risk of
macroalbuminuria, doubling of creatinine levels, and devel-
opment of kidney failure (See Supplementary Tables 7–12
online).
These trials include RCTs in patients with CKD of various
causes, primarily glomerulonephritis,191 African-Americans
with hypertension,177 and patients with advanced CKD (a
GFR of 20–70ml/min/1.73m2).192 A meta-analysis of in-
dividual patient data from 11 RCTs compared antihyperten-
sive regimens including ACE-Is to regimens without ACE-Is
in 1860 patients with predominantly non-diabetic CKD. In
adjusted analyses, ACE-Is were associated with a HR of 0.69
for kidney failure (95% CI 0.51–0.94) and 0.70 for the
combined outcome of doubling of the baseline SCr
concentration or kidney failure (95% CI 0.55–0.88). Patients
with greater urinary protein excretion at baseline benefited
more from ACE-I therapy (P¼ 0.03 for kidney failure and
P¼ 0.001 for the combined outcome).141
The Work Group did not find heterogeneity with regard to
the benefit of ACE-Is according to CKD stage; therefore, the
guideline statements are not divided on this basis. Further-
more, few RCTs with hard CVD or kidney-disease outcomes
randomized patients to a diuretic or another agent in
addition to an ACE-I or ARB; therefore, we have not
included any guideline statements to support this practice. In
fact, one RCT in individuals predominantly without CKD
showed that the risk of doubling of the creatinine level was
higher with an ACE-I–hydrochlorothiazide combination than
with ACE-I–amlodipine.101 The clinical importance of this
end point remains to be determined,193 as it may reflect a
reversible hemodynamic effect. Finally, there is only limited
quality evidence evaluating either differences in ACE-I versus
ARB, or comparison of ACE-I plus ARB versus either ACE-I
or ARB with regard to hard clinical outcomes (Supplemen-
tary Tables 13–15 online).
CVD. Only a few RCTs of BP agents have focused on
CVD outcomes in subjects with CKD (Supplementary
Tables 7–32 online); therefore, most of the data are from
subgroup analyses of CKD patients from general population
studies. Several analyses have shown a benefit of ACE-Is
or ARBs over placebo or another agent, and although most of
these studies were performed in patients with urine albumin
levels below the macroalbuminuria cutoff, there is no
obvious reason why the benefit would not extend to
individuals with macroalbuminuria (Supplementary Tables
7–12 online).
In summary, the data in support of the use of ACE-Is or
ARBs are reasonably strong for preventing progression of
CKD and less so for CVD protection. Notably, they show no
harm of either class of drugs with regard to CVD. Taken
together, the data on both drug classes support a grade 1B
recommendation for ACE-Is or ARBs as a preferred agent in
CKD patients with albumin excretion4300mg per 24 hours
or its equivalent.
RESEARCH RECOMMENDATIONS
K Large RCTs of BP targets are needed in CKD patients
without diabetes (stratified by GFR and albuminuria)
that are powered for clinical outcomes including kidney
failure, CVD events and mortality.
K Large RCTs of BP agents are needed in CKD patients
without diabetes (stratified by GFR and albuminuria)
that are powered for clinical outcomes including kidney
failure, CVD events and mortality.
K Subgroup analyses in new, large-scale RCTs as described
above by specific causes of CKD are needed.
K Studies are needed to examine how intermediate out-
comes for CKD and CVD (i.e., doubling of creatinine
level, change in urine protein level, and development or
regression of left ventricular hypertrophy) track with
clinical outcomes to assess their validity as prognostic
tools and possible surrogate outcomes going forward.
K Development of prediction tools for clinical outcomes in
patients with CKD and testing in clinical trials for
exploration of treatment heterogeneity are encouraged.
K Development of prediction tools for the adverse out-
comes of ACE-Is and ARBs is encouraged.
K Cost-effectiveness analyses of lower BP targets in CKD
patients without diabetes as stratified by GFR and
albuminuria should be conducted.
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